Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1138) 1138
Publication (104) 104
Book / eBook (45) 45
Book Review (14) 14
Book Chapter (7) 7
Magazine Article (5) 5
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1054) 1054
sleep initiation and maintenance disorders - chemically induced (711) 711
male (636) 636
female (630) 630
adult (496) 496
middle aged (416) 416
index medicus (326) 326
sleep initiation and maintenance disorders - drug therapy (308) 308
psychiatry (276) 276
sleep (236) 236
aged (234) 234
insomnia (193) 193
treatment outcome (160) 160
pharmacology & pharmacy (155) 155
clinical neurology (153) 153
adolescent (151) 151
double-blind method (134) 134
animals (131) 131
dose-response relationship, drug (129) 129
sleep - drug effects (119) 119
hypnotics and sedatives - adverse effects (115) 115
neurosciences (114) 114
headache - chemically induced (108) 108
sleep disorders (98) 98
child (96) 96
double-blind (94) 94
nausea - chemically induced (92) 92
hypnotics and sedatives - therapeutic use (88) 88
placebos (87) 87
drug administration schedule (80) 80
time factors (76) 76
depression (75) 75
drug therapy (74) 74
efficacy (71) 71
depressive disorder - drug therapy (68) 68
sleep initiation and maintenance disorders - epidemiology (66) 66
anxiety - chemically induced (65) 65
clinical trials as topic (64) 64
medicine, general & internal (64) 64
sleep stages - drug effects (64) 64
psychiatric status rating scales (62) 62
psychology, clinical (62) 62
risk factors (62) 62
drug therapy, combination (59) 59
sleep initiation and maintenance disorders - physiopathology (58) 58
sleep wake disorders - chemically induced (58) 58
aged, 80 and over (56) 56
neurology (55) 55
research (55) 55
severity of illness index (55) 55
antipsychotic agents - adverse effects (53) 53
zolpidem (53) 53
benzodiazepines (52) 52
sleep initiation and maintenance disorders - psychology (52) 52
serotonin uptake inhibitors - adverse effects (51) 51
therapy (51) 51
electroencephalography (50) 50
fatigue - chemically induced (50) 50
rats (50) 50
schizophrenia - drug therapy (50) 50
young adult (50) 50
antipsychotic agents - therapeutic use (48) 48
benzodiazepines - adverse effects (48) 48
follow-up studies (48) 48
side effects (48) 48
analysis (47) 47
depression - chemically induced (47) 47
surveys and questionnaires (47) 47
safety (46) 46
sleep - physiology (46) 46
article (45) 45
dizziness - chemically induced (45) 45
prevalence (45) 45
pyridines - adverse effects (45) 45
medicine & public health (44) 44
serotonin uptake inhibitors - therapeutic use (44) 44
attention deficit disorder with hyperactivity - drug therapy (43) 43
depression - drug therapy (43) 43
health aspects (43) 43
anti-anxiety agents - adverse effects (42) 42
care and treatment (42) 42
internal medicine (42) 42
polysomnography (42) 42
antidepressants (41) 41
children (41) 41
antidepressive agents - therapeutic use (40) 40
central nervous system stimulants - adverse effects (40) 40
drugs (40) 40
hallucinations - chemically induced (40) 40
pediatrics (40) 40
triazolam - adverse effects (40) 40
sleep initiation and maintenance disorders - etiology (39) 39
sleep initiation and maintenance disorders - diagnosis (38) 38
substance withdrawal syndrome - etiology (38) 38
administration, oral (37) 37
antidepressive agents - adverse effects (37) 37
placebo (37) 37
sleep initiation and maintenance disorders - complications (37) 37
comorbidity (36) 36
drug interactions (36) 36
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (31) 31
UofT at Mississauga - Stacks (9) 9
UofT at Scarborough - Stacks (7) 7
Robarts - Stacks (5) 5
UTL at Downsview - May be requested (4) 4
Providence Healthcare - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Gerstein Science - Reference (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
OISE - Reference (2) 2
OISE - Stacks (2) 2
Scarborough Hospital - General (2) 2
St. Michael's Hospital - Stacks (2) 2
West Park Healthcare Centre - Hospital Department (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Credit Valley Hospital - Reserve desk (1) 1
Credit Valley Hospital - Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Humber River Regional Hospital - Online (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mt Sinai Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
St. Augustine's Seminary - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trillium Health Centre - Reserve desk (1) 1
Trillium Health Centre - Stacks (1) 1
UofT at Mississauga - Missing (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1087) 1087
French (41) 41
German (23) 23
Russian (9) 9
Italian (8) 8
Spanish (8) 8
Japanese (4) 4
Polish (4) 4
Chinese (3) 3
Dutch (2) 2
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Benzodiazepine use and risk of Alzheimer's disease: case-control study
by Billioti de Gage, Sophie and Moride, Yola and Ducruet, Thierry and Kurth, Tobias and Verdoux, Hélène and Tournier, Marie and Pariente, Antoine and Bégaud, Bernard
BMJ (Clinical research ed.), ISSN 0959-8146, 2014, Volume 349, Issue sep09 2, pp. g5205 - g5205
Objectives To investigate the relation between the risk of Alzheimer's disease and exposure to benzodiazepines started at least five years before, considering... 
POPULATION | DEPRESSION | MEDICINE, GENERAL & INTERNAL | SLEEP | DEMENTIA | OLDER-ADULTS | NEUROPSYCHIATRIC SYMPTOMS | HUMAN-MEMORY | DRUGS | NESTED CASE-CONTROL | MILD COGNITIVE IMPAIRMENT | Quebec - epidemiology | Humans | Risk Factors | Male | Anxiety Disorders - chemically induced | Case-Control Studies | Sleep Initiation and Maintenance Disorders - chemically induced | Aged, 80 and over | Alzheimer Disease - epidemiology | Female | Aged | Benzodiazepines - adverse effects | Depressive Disorder - chemically induced | Alzheimer Disease - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
by Sax, Paul E, Dr Prof and Wohl, David, MD and Yin, Michael T, Prof and Post, Frank, MD and DeJesus, Edwin, MD and Saag, Michael, MD and Pozniak, Anton, MD and Thompson, Melanie, MD and Podzamczer, Daniel, MD and Molina, Jean Michel, Prof and Oka, Shinichi, MD and Koenig, Ellen, MD and Trottier, Benoit, MD and Andrade-Villanueva, Jaime, MD and Crofoot, Gordon, MD and Custodio, Joseph M, PharmD and Plummer, Andrew, MS and Zhong, Lijie, PhD and Cao, Huyen, MD and Martin, Hal, MD and Callebaut, Christian, PhD and Cheng, Andrew K, MD and Fordyce, Marshall W, MD and McCallister, Scott, MD and GS-US-292-0104 0111 Study Team and GS-US-292-0104/0111 Study Team
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)
by Vieta, Eduard and Suppes, Trisha and Eggens, Ivan and Persson, Inger and Paulsson, Björn and Brecher, Martin and Trial 126 Study Investigators
Journal of Affective Disorders, ISSN 0165-0327, 2008, Volume 109, Issue 3, pp. 251 - 263
Abstract Background This study examined the efficacy and safety of quetiapine in combination with lithium or divalproex compared with placebo with lithium or... 
Psychiatry | Divalproex | Bipolar disorder | Lithium | Maintenance | Quetiapine | Placebo | MEDICATION | MONOTHERAPY | PSYCHIATRY | quetiapine | MANIA | CONTROLLED 18-MONTH TRIAL | CLINICAL NEUROLOGY | divalproex | lithium | bipolar disorder | THERAPY | MOOD | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | OLANZAPINE | RATING-SCALE | maintenance | placebo | Demography | Disorders of Excessive Somnolence - chemically induced | Nasopharyngitis - epidemiology | Antipsychotic Agents - adverse effects | Humans | Nasopharyngitis - chemically induced | Male | Bipolar Disorder - diagnosis | Sleep Initiation and Maintenance Disorders - chemically induced | Sleep Initiation and Maintenance Disorders - epidemiology | Young Adult | Dibenzothiazepines - therapeutic use | Antipsychotic Agents - therapeutic use | Dibenzothiazepines - adverse effects | Female | Valproic Acid - therapeutic use | Valproic Acid - adverse effects | Headache - chemically induced | Severity of Illness Index | Quetiapine Fumarate | Treatment Outcome | International Cooperation | Bipolar Disorder - drug therapy | Bipolar Disorder - psychology | Lithium Carbonate - therapeutic use | Disorders of Excessive Somnolence - epidemiology | Headache - epidemiology | Lithium Carbonate - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Psychiatric Symptoms in Patients Receiving Dolutegravir
by Fettiplace, Anna and Stainsby, Chris and Winston, Alan and Givens, Naomi and Puccini, Sarah and Vannappagari, Vani and Hsu, Ricky and Fusco, Jennifer and Quercia, Romina and Aboud, Michael and Curtis, Lloyd
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2017, Volume 74, Issue 4, pp. 423 - 431
INTRODUCTION:Psychiatric symptoms (PSs) are reported to occur frequently in people living with HIV and may be associated with specific antiretrovirals. We... 
anxiety | depression | dolutegravir | antiretroviral therapy | suicide | insomnia | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | SAFETY | PREVALENCE | IMMUNOLOGY | GENERAL-POPULATION | DOUBLE-BLIND | HIV-1 INFECTION | NAIVE ADULTS | Psychoses, Substance-Induced | Humans | Anxiety - psychology | Male | Suicidal Ideation | Treatment Outcome | HIV Integrase Inhibitors - administration & dosage | Randomized Controlled Trials as Topic | Sleep Initiation and Maintenance Disorders - chemically induced | Young Adult | Clinical Trials, Phase III as Topic | HIV Integrase Inhibitors - adverse effects | Depression - chemically induced | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Depression - psychology | HIV Infections - drug therapy | Anxiety - chemically induced | Sleep Initiation and Maintenance Disorders - psychology | Clinical Science
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: A meta-analysis of clinical study reports
by Maund, Emma and Guski, Louise Schow and Gøtzsche, Peter C
CMAJ, ISSN 0820-3946, 02/2017, Volume 189, Issue 5, pp. E194 - E203
BACKGROUND: The European Medicines Agency makes clinical study reports publicly available and publishes reasons for not approving applications for marketing... 
WOMEN | DEPRESSION | TRIALS | SSRI | MEDICINE, GENERAL & INTERNAL | PLACEBO | PAROXETINE | Duloxetine Hydrochloride - therapeutic use | Mental Disorders - chemically induced | Risk Assessment | Violence | Humans | Suicidal Ideation | Treatment Outcome | Randomized Controlled Trials as Topic | Sleep Initiation and Maintenance Disorders - chemically induced | Antidepressive Agents - therapeutic use | Psychoses, Substance-Induced - etiology | Female | Anxiety - chemically induced | Urinary Incontinence, Stress - drug therapy | Akathisia, Drug-Induced - etiology | Affective Symptoms - chemically induced | Urinary incontinence | Complications and side effects | Drug therapy | Pharmaceutical industry | Mental health | Prescription drugs | FDA approval | Antidepressants | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study
by Savard, Josée and Ivers, Hans and Savard, Marie‐Hélène and Morin, Charles M
Cancer, ISSN 0008-543X, 05/2015, Volume 121, Issue 10, pp. 1703 - 1711
BACKGROUND Insomnia affects between 30% to 60% of patients with cancer but to the authors' knowledge little is known regarding factors associated with its... 
sleep | cancer treatment | side effects | cancer | longitudinal | insomnia | DEPRESSION | SYMPTOM CLUSTER | FATIGUE | SLEEP DISTURBANCES | CHEMOTHERAPY | BREAST-CANCER | THERAPY | ONCOLOGY | QUALITY-OF-LIFE | HOT FLASHES | Prostatic Neoplasms - radiotherapy | Prospective Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Prostatic Neoplasms - therapy | Sleep Initiation and Maintenance Disorders - chemically induced | Sleep Initiation and Maintenance Disorders - epidemiology | Breast Neoplasms - therapy | Antineoplastic Agents, Hormonal - adverse effects | Canada - epidemiology | Antineoplastic Agents - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Aged, 80 and over | Adult | Female | Surveys and Questionnaires | Prostatic Neoplasms - drug therapy | Severity of Illness Index | Sleep Initiation and Maintenance Disorders - etiology | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Quality of Life | Aged | Longitudinal Studies | Complications and side effects | Care and treatment | Insomnia | Risk factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Symptom incidence, distress, cancer‐related distress, and adherence to chemotherapy among African American women with breast cancer
by Yee, Melissa K and Sereika, Susan M and Bender, Catherine M and Brufsky, Adam M and Connolly, Mary C and Rosenzweig, Margaret Q
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 11, pp. 2061 - 2069
BACKGROUND There is a persistent racial survival disparity between African American (AA) and white women with breast cancer. There is evidence that symptom... 
distress | symptoms | breast cancer | racial disparity | chemotherapy | ADJUVANT CHEMOTHERAPY | RACIAL DISPARITIES | DOSE INTENSITY | CARE | TUMOR CHARACTERISTICS | SUPPORT | ONCOLOGY | WHITE WOMEN | QUALITY-OF-LIFE | OUTCOMES | SURVIVORS | Medication Adherence - psychology | Gastrointestinal Diseases - epidemiology | Gastrointestinal Diseases - psychology | Humans | Middle Aged | Body Image - psychology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - psychology | Fatigue - chemically induced | Stress, Psychological - psychology | Breast Neoplasms - drug therapy | Incidence | Randomized Controlled Trials as Topic | Sleep Initiation and Maintenance Disorders - chemically induced | Sleep Initiation and Maintenance Disorders - epidemiology | Fatigue - epidemiology | Breast Neoplasms - psychology | Adult | Female | Women - psychology | Gastrointestinal Diseases - chemically induced | African Americans - psychology | Sleep Initiation and Maintenance Disorders - psychology | Chemotherapy | Usage | Breast cancer | Diagnosis | Health aspects | African American women | Cancer | Deterioration | Correlation analysis | African Americans | Breast | Adhesion | Emotions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study
by Fausto Roila and Benedetta Ruggeri and Enzo Ballatori and Albano Del Favero and Maurizio Tonato
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 101 - 106
Purpose A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by... 
INDUCED NAUSEA | GUIDELINE UPDATE | ANTAGONIST APREPITANT | EFFICACY | ONCOLOGY | MODERATELY EMETOGENIC CHEMOTHERAPY | TOLERABILITY | CONSENSUS CONFERENCE | ONDANSETRON | HIGH-DOSE CISPLATIN | PLACEBO-CONTROLLED TRIAL | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Heartburn - prevention & control | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Heartburn - chemically induced | Cyclophosphamide - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Sleep Initiation and Maintenance Disorders - prevention & control | Anthracyclines - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | Vomiting - prevention & control | Morpholines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
by Citrome, Leslie
International Journal of Clinical Practice, ISSN 1368-5031, 11/2017, Volume 71, Issue 11, pp. e13030 - n/a
Summary Objective Deutetrabenazine is a deuterated formulation of tetrabenazine. The aim of this systematic review is to describe the efficacy, tolerability... 
Adrenergic Uptake Inhibitors - adverse effects | Tetrabenazine - analogs & derivatives | Tardive Dyskinesia - drug therapy | Adrenergic Uptake Inhibitors - therapeutic use | Humans | Nasopharyngitis - chemically induced | Vesicular Monoamine Transport Proteins - antagonists & inhibitors | Treatment Outcome | Randomized Controlled Trials as Topic | Sleep Initiation and Maintenance Disorders - chemically induced | Numbers Needed To Treat | Tetrabenazine - adverse effects | Tetrabenazine - therapeutic use | Enzyme inhibitors | Tardive dyskinesia | Analysis | Movement disorders | Drugs | Posters | Clinical trials | Labelling | Rhinopharyngitis | Systematic review | Pharmacology | Tetrabenazine | Vesicular amine transporter | Patients | Sleep disorders | Randomization | Side effects | Insomnia | Monoamine transporter | Adults | Deuteration | Safety | Transporter | Dyskinesia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A Unified Model of Performance for Predicting the Effects of Sleep and Caffeine
by Ramakrishnan, Sridhar and Wesensten, Nancy J and Kamimori, Gary H and Moon, James E and Balkin, Thomas J and Reifman, Jaques
Sleep, ISSN 0161-8105, 10/2016, Volume 39, Issue 10, pp. 1827 - 1841
Abstract Study Objectives: Existing mathematical models of neurobehavioral performance cannot predict the beneficial effects of caffeine across the spectrum of... 
Chronic sleep restriction | Biomathematical model | Caffeine model | PVT | Total sleep deprivation | caffeine model | biomathematical model | total sleep deprivation | PSYCHOMOTOR VIGILANCE TEST | COGNITIVE PERFORMANCE | OPERATIONS | chronic sleep restriction | VULNERABILITY | ALERTNESS | NEUROSCIENCES | MODAFINIL | DEXTROAMPHETAMINE | CLINICAL NEUROLOGY | IMPAIRMENT | DEPRIVATION | Predictive Value of Tests | Wakefulness - drug effects | Caffeine - administration & dosage | Humans | Middle Aged | Caffeine - adverse effects | Male | Psychomotor Performance - physiology | Sleep Initiation and Maintenance Disorders - chemically induced | Dose-Response Relationship, Drug | Sleep Deprivation - diagnosis | Young Adult | Adult | Female | Sleep - physiology | Models, Theoretical | Sleep Initiation and Maintenance Disorders - diagnosis | Sleep Deprivation - chemically induced | Psychomotor Performance - drug effects | Sleep - drug effects | Cross-Over Studies | Sleep Deprivation - physiopathology | Adolescent | Wakefulness - physiology | Sleep Initiation and Maintenance Disorders - physiopathology | Sleep deprivation | Caffeine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
by Nguyen, Alain and Calmy, Alexandra and Delhumeau, Cecile and Mercier, Isabelle and Cavassini, Matthias and Mello, Aurelie F and Elzi, Luigia and Rauch, Andri and Bernasconi, Enos and Schmid, Patrick and Hirschel, Bernard
AIDS, ISSN 0269-9370, 07/2011, Volume 25, Issue 12, pp. 1481 - 1487
Background: Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavorable blood lipid profile. We investigated the effect of replacing EFV with... 
raltegravir | neuropsychiatric side-effects | cross-over | efavirenz | preference | INFECTIOUS DISEASES | SLEEPINESS | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | NEVIRAPINE | INDIVIDUALS | THERAPY | VIROLOGY | PHARMACOKINETICS | QUALITY-OF-LIFE | HIV-1 INFECTION | INHIBITOR | RITONAVIR | HIV Infections | Humans | Middle Aged | Male | Anxiety Disorders - chemically induced | Sleep Initiation and Maintenance Disorders - chemically induced | Pyrrolidinones - administration & dosage | Adult | Female | Surveys and Questionnaires | Anxiety Disorders - drug therapy | Raltegravir Potassium | HIV Protease Inhibitors - adverse effects | Pyrrolidinones - adverse effects | Benzoxazines - administration & dosage | Drug Administration Schedule | HIV-1 - drug effects | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Anxiety Disorders - psychology | Antiretroviral Therapy, Highly Active | Cross-Over Studies | Sleep Initiation and Maintenance Disorders - drug therapy | Practice Guidelines as Topic | Sleep Initiation and Maintenance Disorders - psychology | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial
by Kane, J and Canas, F and Kramer, M and Ford, L and Gassmann-Mayer, C and Lim, P and Eerdekens, M
Schizophrenia Research, ISSN 0920-9964, 2005, Volume 90, Issue 1, pp. 147 - 161
Abstract Background Paliperidone extended-release tablet (paliperidone ER) is an investigational oral psychotropic developed for schizophrenia treatment. It... 
Psychiatry | Schizophrenia | Paliperidone ER | Efficacy | Tolerability | Atypical antipsychotic | METAANALYSIS | HALOPERIDOL | PSYCHIATRY | RISPERIDONE | schizophrenia | paliperidone ER | efficacy | ANTIPSYCHOTICS | SOCIAL PERFORMANCE SCALE | tolerability | DOUBLE-BLIND | QUALITY-OF-LIFE | ONSET HYPOTHESIS | OLANZAPINE | atypical antipsychotic | Dyskinesia, Drug-Induced - etiology | Pyrimidines - administration & dosage | Tachycardia - chemically induced | Humans | Middle Aged | Paliperidone Palmitate | Male | Treatment Outcome | Patient Dropouts | Schizophrenic Psychology | Isoxazoles - administration & dosage | Randomized Controlled Trials as Topic | Sleep Initiation and Maintenance Disorders - chemically induced | Antipsychotic Agents - administration & dosage | Dose-Response Relationship, Drug | Psychiatric Status Rating Scales | Drug-Related Side Effects and Adverse Reactions | Adult | Female | Schizophrenia - drug therapy | Delayed-Action Preparations | Psychotropic drugs | Clinical trials | Clinical psychiatry | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights